Licensing Partner sought for new class of Antibiotics effective against common and severe infections

OFFER from Germany, reference: TODE20171228001, valid from 09-01-2018 untill 10-01-2019

  • Title:
    Licensing Partner sought for new class of Antibiotics effective against common and severe infections
  • Start date:
    9 januari 2018
  • End date:
    10 januari 2019
  • Summary:
    A German University is searching a licensing partner for a newly developed class of Antibiotics against Gram-positive bacteria. Among them are some of the most dangerous pathogens for humans. It can be applied as an antibiotic or as a probiotic. Advantages of this new class are very rapid killing of pathogenic bacteria, low toxicity and an assumed targeting of structures, so far not covered by established antibiotics.
  • Description:
    A German Research Group of a University has identified a new class of Antibiotics, showing extraordinary effects in animal models against highly-resistant bacteria, called Gram-positive Bacteria.
    Among Gram-positive bacteria are some of the most dangerous pathogens for humans. Especially Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for a high percentage of hospital-acquired deadly infections, because of its resistance against common Antibiotics. The new found antibiotic class offers the possibility of developing new pharmaceutically applicable antibiotics.
    On the other side, the newly identified naturally human-associated bacterial antibiotic producer strain (S. lugdunensis IVK28 wild type) could be applied as a probiotic cure before patients enter hospital. This could avoid costly decolonization of human commensal bacteria before surgery. Also it could replace usual antibiotics and thus reduce the hospitalization duration.
    The antibiotic producer strain is applicable in human medicine but also in veterinary medicine against a broad range of Gram-positive bacteria. A patent application covering the chemical structures, the genetic background of the producer strain, the bioactivity of the new substances and their synthesis has been filed.
    The University is looking for a licensing partner to take the antibiotic and/or antibiotic producer strain to a new medicine. Ideally this is a pharmaceutical company with experiences in the development of marketable medications.
Partner Sought
  • Type of Partnership Considered:
    License agreement
  • Technical Specification or Expertise Sought:

    Type of Partner: Industrial partner
    Activity of Partner: Pharmaceutical company
    Role of Partner: Licensing of the antibiotic substance for the development of a marketable product.

    SME 11-50,>500 MNE,251-500,SME 51-250,>500

  • Development stage:
    Prototype available for demonstration
  • IPR Status:
    Patent(s) applied for but not yet granted
  • Market keywords:
    Drug delivery and other equipment
    'Surgery and Anaesthesiology
  • Technology keywords:
    Virus, Virology/Antibiotics/Bacteriology
  • NACE keywords:
    Other research and experimental development on natural sciences and engineering
  • Advantages and Innovations:
    - Very rapid killing of pathogenic bacteria even in the non-growing state. Application of 1 microgram/milliliter (MIC) leads to complete killing of bacteria in vitro.
    - Efficiency of the pure compound already shown in a topical mouse model
    - Low toxicity: First data point to a low cytotoxic potential against human cells.
    - Preliminary data suggest, that molecular target might be a biochemical structure so far not targeted by established antibiotics.
  • Type and Size of Organisation:
  • Already Engaged in Trans-National Cooperation
  • Year Established:
  • Turnover:
  • Country of origin:
  • Languages spoken
    • English
    • German
    • Spanish